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The Bifidobacteria show great diversity in the cell surface architecture which may
influence the physicochemical properties of the bacterial cell and strain specific
properties. The immunomodulatory role of bifidobacteria has been extensively studied,
however studies on the immunoreactivity of their protein molecules are very limited.
Here, we compared six different methods of protein isolation and purification and
we report identification of immunogenic and immunoreactive protein of two human
Bifidobacterium longum ssp. longum strains. We evaluated potential immunoreactive
properties of proteins employing polyclonal sera obtained from germ free mouse, rabbit
and human. The protein yield was isolation method-dependent and the reactivity of
proteins detected by SDS-PAGE and Western blotting was heterogeneous and varied
between different serum samples. The proteins with the highest immunoreactivity were
isolated, purified and have them sequenced. Among the immunoreactive proteins
we identified enolase, aspartokinase, pyruvate kinase, DnaK (B. longum ssp. longum
CCM 7952) and sugar ABC transporter ATP-binding protein, phosphoglycerate kinase,
peptidoglycan synthethase penicillin-binding protein 3, transaldolase, ribosomal proteins
and glyceraldehyde 3-phosphate dehydrogenase (B. longum ssp. longum CCDM 372).
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INTRODUCTION
Bifidobacteria are nonpathogenic, anaerobic, non-motile, non-
sporulating, non-gas producing, branched rod-shaped Gram-
positive bacteria highly represented in the normal microbiota
of the human and animals gastrointestinal tract. They were
first isolated from feces of a breast-fed infant by Tissier in
1899, and then named Bacillus bifidus (Tisseir, 1900). The
Bifidobacterium genus comprises 48 species, exhibits a wide
spectrum of metabolic properties and possess genomes of a high
G+C content (60%) (Ventura et al., 2007; Endo et al., 2012;
Killer et al., 2009, 2011). They are widely used in food and
pharmaceutical industry as a synbiotic or probiotics due to their
health-promoting effects on the human host (Gaggia et al., 2011).
Certain Bifidobacteria exert a range of health benefits, including
the regulation of intestinal microbial homeostasis, the inhibition
of pathogens and harmful bacteria that colonize and/or infect
the gut mucosa, the modulation of local and systemic immune
responses, the repression of procarcinogenic enzymatic activities
within the microbiota, the production of vitamins, and the
bioconversion of a number of dietary compounds into bioactive
molecules (Singh et al., 1997; Picard et al., 2005). It has been
already accepted that probiotic effects of Bifidobacterium strain
is strictly strain dependent and should not be assigned to
other strains, even from the same species. For example, B.
longum BB536 is claimed to alleviating symptoms of allergy
by promoting Th1 response, whereas B. longum ACTT15707
showed a strong induction of interleukin 10 (IL-10) and could
help in the treatment and prevention of gastrointestinal infection
(Sanz et al., 2007). Recently, Srutkova et al. (2015) have shown
that B. longum ssp. longum CCM 7952, but not B. longum ssp.
longum CCDM 372, protected mice from the development of
experimental colitis suggesting that careful selection might be
crucial in providing beneficial outcome in clinical trials with
probiotics bacteria.
Our understanding of bifidobacteria-host interactions, their
symbiosis and how bacteria are able to differentially modulate
the host immune response is growing, but it is still in its
infancy. Little is known about the molecular mechanism of this
relationship and the specific bacterial components responsible
for the beneficial effect are generally unrecognized. The immune
effects of probiotics can be exerted directly by live microbial cells,
but also by bacterial cell components localized either in the cell
wall or membrane fraction or secreted compounds.
Bifidobacterium produces plenty of cell-associated molecules
which may play a key role in host-microbiota interactions
i.e., polysaccharide antigens which may contribute in bacterial
adherence to the host cells (Salazar et al., 2009; Fanning et al.,
2012), pili-like structures mediate bacterial colonization (Turroni
et al., 2013) or a serpin-like protease inhibitor taking part in host-
microbe interaction in the gut (Turroni et al., 2010). Extracellular
proteins produced by bifidobacteria are known to be either
released into environment or surface-attached. They may be
responsible for the enhancement of the mucosal barrier and
immunomodulation due to the possibility of direct interaction
with host epithelial or immune cells (Dylus et al., 2013). Some
other proteins, such as cytosolic proteins: metabolic enzymes,
housekeeping, ribosomal proteins and molecular chaperones
known as moonlight protein can be also found to be involved
in immune cells stimulation, interactions with other bacteria or
adhesion phenomena (Henderson and Martin, 2014). It has been
demonstrated that in addition to compounds released to culture
supernatants, which have clearly an immunomodulation effect
(Hoarau et al., 2006), also DNA from different probiotic strains
led to cytokine induction (Lammers et al., 2003). However, still
the studies on the immunoreactivity of the Bifidobacterium cell
components are scarce.
The aim of this study was to identify immunoreactive proteins
of two Bifidobacterium strains: B. longum ssp. longum CCM
7952 and CCDM 372 and compare the efficacy of six different
methods used for proteins isolation. The immunoreactivity of
proteins was tested by SDS-PAGE and Western blotting using
sera from mice mono-colonized with studied strains, sera from
rabbits immunized against whole bacteria of studied strains and
non-immune human sera. As a result, we have found several
major immunoreactive proteins recognized by human sera and
an immunogenic proteins which elicit antibody response in mice
or rabbit immune system. We also indicated that two methods,
namely Heilmann method and extraction by LiCl are usefulness
to isolate the immunoreactive proteins.
MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
Bifidobacterium longum ssp. longum CCDM 372 and
Bifidobacterium longum ssp. longum CCM 7952 were originally
isolated from feces of breast-fed healthy child. Both strains
were provided by Culture Collection of Dairy Microorganisms
(Milcom, Czech Republic). The isolates were cultivated in
MRS medium (Difco) supplemented with 0.05% L-cysteine-
hydrochloride (Millipore) at 37◦C in anaerobic conditions
(GasPak EZ Anaerobe Container System BD, USA) for 48 h.
Lactobacillus paracsei LOCK 0912 for sera preparation was
isolated form feaces of healthy newborn and cultivated in MRS
medium (Difco) at 37◦C in microaerophilic conditions for
48 h. Cells were harvested by centrifugation (6000 g for 15min)
(Heraeus Contifuge Stratus, Thermo Scientific, Germany) and
washed two times in PBS buffer (phosphate buffered saline pH
7,4). Strain B. longum ssp. longum CCM 7952 is characterized
by high amount of slime production, therefore, before protein
isolation, the culture was centrifuged at 14,500 g several times to
get rid of salts and bacterial polysaccharides.
Serum Samples
Mouse Non-immune and Immune Sera
Mouse serum was obtained from germ-free mouse (GF) and
gnotobiotic mice mono-colonized with B. longum ssp. longum
CCM 7952 or B. longum ssp. longum CCDM 372 strains. Germ-
free BALB/c mice were kept under sterile conditions in Trexler-
type plastic isolators, exposed to 12:12-h light-dark cycles and
supplied with autoclaved tap water and 50 kGy irradiated sterile
pellet diet Altromin 1410 (Altromin, Lage, Germany) ad libitum.
Fecal samples were weekly controlled for microbial molds and
yeast contamination by standard microbiological methodology.
Frontiers in Microbiology | www.frontiersin.org 2 September 2016 | Volume 7 | Article 1537
Górska et al. Immunoreactive Proteins of Bifidobacterium
Eight-week-old GF mice were colonized with a single dose
(2 × 108 CFU) of freshly grown Bifidobacterium strains in
200 µl of sterile PBS by intragastric administration. Stability
of colonization was checked by plating of feces on MRS agar
supplemented with l-cysteine hydrochloride (0.5 g/l) and CFU
were counted after anaerobic cultivation for 48 h at 37◦C. Animal
experiments were approved by the Animal Experimentation
Ethics Committee of the Institute of Microbiology of the
Academy of Sciences of the Czech Republic and conducted in
accordance with the “European Convention for the Protection of
Vertebrate Animals used for Experimental and other Scientific
Purposes (CETS No.: 123).”
Rabbit Immune Sera
Rabbit sera were obtained from Termond White rabbit
immunized with bacterial mass of B. longum ssp. longum CCM
7952 (R-7952), B.longum ssp. longum CCDM 372 (R-372) or
L. paracsei LOCK 0912 (R-0912) as described before (Górska
et al., 2016). The experiments were approved by the 1st Local
Committee for Experiments with the Use of Laboratory Animals,
Wroclaw, Poland (number 12/2012).
Human Sera
Human adults sera were obtained from healthy volunteers from
Military Blood Donors Centre in Wroclaw (Poland, pooled n =
10), whereas human umbilical cord sera from healthy women
(pooled n = 10) were obtained from the Obstetric Clinic of the
Medical University of Wroclaw and human adults sera from
patients with Clostridium difficile infection (pooled n = 10) were
obtained from 4th Millitary Hospital in Wrocław. The use of sera
samples was approved by the Medical Ethics Committee of the
Medical University of Wroclaw (number KB-882-2012 and KB-
631/2015) and was conducted in accordance with the Helsinki
Declaration of 1975. Samples were obtained with patients’ written
informed consent.
Protein Isolation
Six different methods for protein isolation were tested. The
Bifidobacterium cell pellets (1 g) were suspended in 5 ml of:
I. 10mM EDTA (Sigma-Aldrich; 30min., 45◦C) according to
McCoubrey and Poxton (2001),
II. 0,2M glycine (Sigma-Aldrich) pH 2,2 (30min, RT)
according to Wright et al. (2005),
III. 1M LiCl (Sigma-Aldrich; 30min, RT) according to McCoy
et al. (1975),
IV. 8M urea (Sigma-Aldrich; 30min, RT) according to McCoy
et al. (1975),
V. 5M guanidine hydrochloride (Sigma-Aldrich; 2 h, RT)
according to Poxton and Byrne (1981),
VI. 0.5M Tris-HCl (Serva; pH = 6,8)/SDS (Serva; 0,08%
w/v)/glycerol (POCh; 20% v/v)/1mM β-mercaptoethanol
(Sigma-Aldrich) (v/v) and boiled for 5 min according to
Heilmann et al. (1996).
After centrifugation (6000 × g for 5min), proteins were
precipitated from the resulting supernatant using 3 volumes of
cold 95% ethanol (POCh). Followed by overnight incubation
at 4◦C, the precipitated proteins were centrifuged (12,000 × g),
dissolved in water and dialyzed for 48 h. Protein concentration
was measured using the Lowry’s method (Lowry et al., 1951). The
prepared protein samples were stored in 1mg aliquots at−70◦C.
SDS-PAGE and Western Blot Conditions
Equal amounts of proteins samples (10 µg) were analyzed on
SDS-PAGE using 5–12.5% gels according to Laemmli (1970)
using Tris-Glycine-SDS as running buffer and run for about
2 h at 100V (Mini-Protean Tetra Cell 165–8001; Bio-Rad,
USA). After staining with Coomassie Brilliant Blue (Serva)
or soaked in transfer buffer (10 mM Tris-HCl, 150mM
glycine, 20% methanol (POCh) pH 8.3) for 30min, gels were
transferred to a polyvinylidene difluoride membrane (Millipore)
for immunoblotting (for 1 h at 100V). Following transfer, the
membrane was blocked with 1% of bovine serum albumin
(BSA, KPL), dissolved in phosphate buffered saline, and then
incubated with selected sera in 1% BSA for 2 h at RT. We
used different dilutions of sera but the most effective was:
for rabbit sera 1:5000, mouse sera 1:1000 and for human sera
1:500 (reproducible results, without the Hook effect). After
washing in PBS containing 0.25% Tween 20 (PBS-T, Institute
of Immunology and Experimental Therapy, PAN) for several
times, captured antibodies against protein were detected by
incubating the membranes with alkaline phosphatase-labeled
goat anti-mouse/rabbit/human IgG antibody (Sigma-Aldrich)
diluted 1:10,000. Finally, themembranes were washed as six times
with PBS-T, and visualized with solution containing nitro blue
tetrazolium (NBT, Roth), 5-bromo-4-chloro-3-indolyl phosphate
(BCIP, Roth), and MgCl2 (POCh) for 5 s. Image acquisition
(exposure time 1–4min) was performed using VersaDoc Imaging
System (Bio-Rad).
Protein Identification
Protein identification was performed as previously described by
us (Górska et al., 2016). Briefly, the immunoreactive protein were
separated and purified using Prep-Cell apparatus (Model 491
Bio-Rad). Individual spots were cut out from gels and submitted
to tryptic digestion, and analyzed by mass spectrometry
(spectrometer LC-MS/MS Orbitrap, Thermo). Mascot (Matrix
Science, London, UK, http://www.matrixscience.com) and
statistical analysis were used to identify proteins from peptide
mass fingerprints. All searches were performed against the
database for Bifidobacterium species. Immunoreactivity of
separated proteins was proved using immunoblotting.
RESULTS
To investigate the immunoreactive proteins of B. longum CCM
7952 (CCM 7952) and B. longum CCDM 372 (CCDM 372) and
to identify the differences between these strains we analyzed
and compared the profile of reactive proteins obtained with six
different methods. The concentration of the protein in extracts
varied profoundly and depended on methods and tested strain
(Table 1). Generally, we obtained proteins from CCDM 372 with
higher yield than from CCM 7952 strain. The protein extracts
were run on SDS-PAGE gels and representative results are shown
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TABLE 1 | The protein concentration in extracts of B. longum ssp. longum CCM 7952 and CCDM 372.
Method of isolation/Bifidobacterium 10 mM EDTA 0,2M glycine 1M LiCl 8M urea 5M guanidine Heilmann
strains hydrochloride methods
B. longum ssp. longum CCM 7952 26,3 [µg/ml] 7,1 [µg/ml] 14,0 [µg/ml] 60,9 [µg/ml] 318,6 [µg/ml] 9835 [µg/ml]
B. longum ssp. longum CCDM 372 35,4 [µg/ml] 48,4 [µg/ml] 182,0 [µg/ml] 383,8 [µg/ml] 551,5 [µg/ml] 18238 [µg/ml]
in Figure 1. The profiles varied depending on the isolation
method, however we observed several main bands that appeared
repeatedly. The samples were immobilized on polyvinylidene
difluoride membranes and submitted to immunoblot analysis.
The incubation with different immune and non-immune sera
revealed the presence of multiple immunoreactive proteins,
however only in extracts of four methods, namely: III–1 M LiCl,
IV–8M urea, V–5M guanidine hydrochloride and VI–Heilmann
method. We performed detailed analysis restricted for this four
extracts due to the presence of strong immunoreactive bands.
In case of mouse sera, we observed that neither protein
extracts of CCDM 372 nor CCM 7952 reacted with non-immune
sera from germ-free mouse or germ-free mouse mono-colonized
with CCM 7952 strain. However, a protein with the molecular
weight of about 40 kDa isolated from strain CCDM 372 by
Heilmann method (Heilmann et al., 1996) reacted with sera
obtained from mice mono-colonized with CCDM 372 strain
(Figure 2).
To determine potential immunogenic proteins, we
immunized rabbits with whole cells of B. longum ssp. longum
CCM 7952 or B. longum ssp. longum CCDM 372 and obtained
polyclonal sera against them: R-7952 and R-372, respectively.
We observed that both polyclonal rabbit sera reacted with
extract of both strains, however the profiles were quite variable,
emphasizing the differences in strains. In case of B. longum
ssp. longum CCM 7952, we detected one strong reaction of
protein with molecular weight of about 43 kDa (Figure 3B)
reacting with homologous sera R-7952. It must be underline
that reactive protein was successfully isolated using Heilmann
method (Heilmann et al., 1996) but not by other methods
(Figure 3A). However, we observed three strong bands with
the molecular weight of about 67 kDa (Figure 3C, line 1, 2,
3), 55 kDa (Figure 3C line 2, 3), 20 kDa (Figure 3C, line 2, 3)
cross-reacting with sera against strain B. longum ssp. longum
CCDM 372. Interestingly, there was no reaction of protein
isolated using Heilmann method (Figure 3D).
Strain B. longum ssp. longum CCDM 372 produced several
immunoreactive proteins, which reacted with homologous sera
R-372, as well as with sera against strain CCM 7952, namely
protein with molecular weight of about 94 kDa (Figure 4), 67
kDa (Figures 4A,C line, line 1, 2, 3), 55 kDa (Figure 4A line
3, Figure 4B line 1, 2, 3), 43 kDa (Figures 4A–D), 35 kDa
(Figure 4A line 3, Figure 4C, line 1, 3), and a few between 14 and
25 kDa (Figures 4B–D).
Considering human sera, we didn’t observed reactivity of
protein extracts with healthy adult sera or cord blood sera, but
we noticed a reactivity of proteins with molecular weight of
about 94 and 45 kDa isolated from CCDM 372 strain with
sera from patients with active Clostridium difficille infection
(Figure 5). We also tested the cross-reactivity with rabbit sera
against Lactobacillus species and we found a broad reactivity of
protein isolated from both strains with molecular weight around
60 kDa (Figure 6).
The protein extracts were purified using electrophoretic
preparation using Prep-Cell apparatus and re-analyzed in
Western blot. The representative results are shown on Figures 7,
8. Spots showing strong immunoreactivity features were cut from
the gel and analyzed in LC-MS/MS. Proteins were identified
by comparative analysis of peptides masses (NCBI, UniProt
databases) using MASCOT and statistical analysis. Results of
sequencing shown as most likely homologs of isolated and
analyzed proteins are summarized in Table 2.
The immunogenic spot with molecular weight around
43 kDa isolated from B. longum ssp. longum CCM 7952
reacted with homologous sera was identified as enolase (38%
protein sequence coverage), while other protein cross-reacted
with sera against B. longum ssp. longum CCDM 372 were
identified as aspartokinase (47%), pyruvate kinase (70%),
molecular chaperon DnaK (30%). It is noteworthy to highlight
that immunoreactive spot with molecular weight around
40 kDa isolated from CCDM 372 strain reacted as the only
one with sera from gnotobiotic mice colonized with this
strain was identified as sugar ABC transporter ATP-binding
protein (37% protein sequence coverage). We observed
the highest protein sequence coverage of 66 and 55 kDa
proteins isolated from B. longum ssp. Longum CCDM 372.
This proteins have been identified as the penicillin-binding
protein 3 peptidoglycan synthetase (65% protein sequence
coverage) and pyruvate kinase (53% protein sequence coverage),
respectively. The spots of 43 and 35 kDa of CCDM 372 were
characterized by a low homology with phosphoglycerate
kinase (39%) and transaldolase (24%), respectively. It has
to be underline, that all above mentioned protein were
isolated regardless of the chosen method. However, when
we analyzed the protein with small molecular weight (less
than 30 kDa) we observed a differences. Surprising, by
method VI we were able to isolate from strain CCDM 372
two immunoreactive protein, namely 1-(5-phosphoribosyl)-
5-[(5-phosphoribosylamino)methylideneamino] imidazole-4-
carboxamide isomerase (50% protein sequence coverage) and
50S ribosomal protein L5 (40% protein sequence coverage),
whereas by method III we isolated three completely different
proteins: 30S ribosomal protein S9, 30S ribosomal protein S16
and 59S ribosomal protein L15 with 73, 79, and 60% protein
sequence coverage, respectively. The immunoreactive protein
with molecular weight about 45 kDa of CCDM 372 strain
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FIGURE 1 | SDS-PAGE profile of proteins isolated from Bifidobacterium longum ssp. longum CCM 7952 (A) and CCDM 372 (B) using different
methods: M, molecular mass marker; I, 10 mM EDTA; II, 0,2M glycine; III, 1M LiCl; IV, 8M urea; V, 5M guanidine hydrochloride; VI, Heilmann methods.
Gels were stained with Coomassie Brilliant Blue.
FIGURE 2 | Immunoblotting of proteins isolated from analyzed strains: M, molecular mass marker [kDa]; line 1, B 372 extract of method III; line 2, B
367 extract of method III; line 3, B 372 extract of method IV; line 4, B 367 extract of method IV; line 5, B 372 extract of method V; line 6, B 367 extract of
method V; line 7, B 372 extract of method VI; line 8, B 367 extract of method VI with sera from gnotobiotic mice mon-colonized with Bifidobacterium
longum ssp. longum CCDM 372.
reacting with human sera from patients with acute Clostridium
difficile infection was recognized as glyceraldehyde 3-phosphate
(40%). Interestingly, spot with molecular mass of 60 kDa
from CCDM 372 and CCM 7952 reacting with sera against L.
paracasei LOCK 0912 was identified as hypothetical protein
BIFLAC_06461 (30%).
DISCUSSION
The insight into the Bifidobacterium–host interaction
mechanism, should be elucidated by identification the biological
function of bacterial components like polysaccharide or
proteins. It is believed that these antigens play a crucial role
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FIGURE 3 | Immunoblotting of proteins isolated from Bifidobacterium longum ssp. longum CCM 7952. M, molecular mass marker [kDa]; line 1, protein
extract of method III; line 2, protein extract of method IV; line 3, protein extract of method V; line 4, protein extracts of method VI; with sera against Bifidobacterium
longum ssp. longum CCM 7952 (A,B) and Bifidobacterium longum ssp. longum CCDM 372 (C,D). These images were taken from different blots, merged and the
appropriate scaling was used.
FIGURE 4 | Immunoblotting of proteins isolated from Bifidobacterium longum ssp. longum CCDM 372. M, molecular mass marker [kDa]; line 1, protein
extract of method III; line 2, protein extract of method IV; line 3, protein extract of method V; line 4, protein extracts of method VI; with sera against Bifidobacterium
longum ssp. longum CCM 7952 (A,B) and Bifidobacterium longum ssp. longum CCDM 372 (C,D). These images were taken from different blots, merged and the
appropriate scaling was used.
in the first line of the contact with host cells i.e., they are
involved in the intestinal colonization by facilitating contact
with epithelium cells and modulate the immune response.
However, our knowledge about immunoreactive proteins of
Bifidobacterium strains are poor. Recently, Talja et al. (2014)
established the prevalence of serum IgG, IgM, and IgA antibodies
specific for Bifidobacterium adolescentis and Bifidobacterium
longum proteins in young children with or without type
1 diabetes, however without their detail characterization.
In our studies we focused on identification of potentially
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FIGURE 5 | Immunoblotting of proteins isolated from Bifidobacterium longum ssp. longum CCM 7952 (A) and CCDM 372 strain (B). M, molecular mass
marker [kDa]; line 1, protein extract of method III; line 2, protein extract of method IV; line 3, protein extract of method V; line 4, protein extracts of method VI; with
human sera obtained from patients with acute Clostridium difficile. These images were taken from different blots, merged, and the appropriate scaling was used.
FIGURE 6 | Immunoblotting of proteins isolated from Bifidobacterium longum ssp. longum CCM 7952 (line 1–4) and CCDM 372 (5–8) strain. M,
molecular mass marker [kDa]; line 1, 5, protein extract of method III; line 2, 6, protein extract of method IV; line 3, 7, protein extract of method V; line 4, 8, protein
extracts of method VI; with rabbit sera against Lactobacillus paracasei LOCK 0912.
immunoreactive/immunogenic proteins of two strains isolated
from human origin: Bifidobacterium longum ssp. longum CCM
7952 and Bifidobacterium longum ssp. longum CCDM 372
using electrophoretic, immunoblotting and mass spectrometry
method. The reactivity with different mouse, human or
immunized rabbit sera was heterogeneous and varied between
methods of isolation and serum samples. This could be explained
by a distinct mechanism of each vaccination or host immune
system. First, we noticed that the proteins isolated from strain
B. longum ssp. longum CCDM 372 are recognized by different
mouse, rabbit or human sera, whereas those from strain CCM
7952 reacted only with immunized rabbit sera. Second, strain
CCDM 372 can induce the production of antibodies in mono-
colonized gnotobiotic mice mouse compared to the strain CCM
7952. Moreover, the detected immunoreactive bands isolated
from strain CCDM 372 show the cross-reactivity with antibodies
against Lactobacillus species and sera of patients withClostridium
difficile infection. This observation may suggested, that the large
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FIGURE 7 | The SDS-PAGE profile of a separated proteins isolated from Bifidobacterium longum ssp. longum CCDM 372 in the presence of
M-molecular mass marker [kDa] by continuous-elution electrophoresis (Prep-Cell apparatus Model 491 Bio-Rad). Samples are electrophoresed through a
cylindrical gel. As molecules migrate through the gel matrix, they separate into bands. Individual bands migrate off the bottom of the gel where they pass directly into
the patented elution chamber for collection. The resulting liquid fractions (2ml) were pooled (5 fractions), dried and analyzed on SDS-PAGE. Gels were stained with
Coomassie Brilliant Blue.
amount of polysaccharide slime surrounding the bacterial cell of
CCM 7952 strain is probably shielding other surface molecules
from host immune cells and suppress antibody responses against
them. This is in line with our previously studies of Lactobacilli
proteins and polysaccharides (Fanning et al., 2012; Górska et al.,
2014, 2016). Moreover, we showed that specific proteins isolated
form tested strains are strains-specific i.e., enolase, whereas other
like pyruvate kinase share a cross-reactivity.
Regarding the immunoreactive protein identified in this
paper, most of them are well-known as highly conserved
cytoplasmic or ribosomal proteins. However, they could be very
often exposed on the bacterial surface to take an additional
activities, e.g., they could be responsible for health benefit
to the host, can be involved in adhesion to epithelium cells
or interaction with plasminogen (Wang et al., 2013). The
proteins, which have been found to serve two or more
functions are described as moonlighting proteins. Mostly,
the studies on moonlighting proteins concern the pathogenic
bacteria like Streptococcus pyogenes, Mycoplasma pneumoniae,
enteropathogenic Escherichia coli, Staphylococcus aureus and
fungi or parasites (Henderson, 2014; Karkowska-Kuleta and
Kozik, 2014) and recently, research has focused on the
roles of moonlighting proteins in probiotics (Lebeer et al.,
2010).
The immunogenic protein of strain CCM 7952 was identified
as enolase. Candela et al. (2009) demonstrated that four
bifidobacterial species, a health-promoting member of the
human intestinal microbiota: B. longum, B. bifidum, B. breve,
and B. lactis share an enolase on a cell surface and plasminogen-
binding activity. Recently, Wei et al. (2014), identified that
enolase and elongation factor Tu serve as surface receptors for B.
longum NCC2705 binding to human plasminogen which could
inhibit the adhesion of B. longum NCC2705 to Caco-2 cells
and suggested that these enzymes are involved in the protective
role played by B. longum NCC2705 in defense against enteric
pathogens. Interestingly, the surface enolase may not only play
a role as a receptor for human plasminogen, but also as a
fibronectin-binding protein (Castaldo et al., 2009).
FIGURE 8 | The selected immunoblots of separated proteins isolated
from Bifidobacterium longum ssp. longum CCDM 372 reacting with
homologous serum. Line 2, fraction 2; line 3, fraction 3; line 4, fraction 4; line
11–14, pooled fraction 11, 12, 13, and 14 obtained by continuous-elution
electrophoresis (Figure 7). These images were taken from different blots,
merged, and the appropriate scaling was used.
Apart from immunogenic enolase, the main immunoreactive
proteins of B. longum ssp. longum CCM 7952 were identified as
aspartokinase, pyruvate kinase and molecular chaperon DnaK.
Chaperon DnaK from B. animalis subsp. lactis BI07 has been
visualized on the bacterial cell surface and the recombinant DnaK
protein showed a high affinity for human plasminogen (Candela
et al., 2010).
Our most striking observation was that, colonization of germ-
free mouse with B. longum ssp. longum CCDM 372 elicited
antibodies against 40 kDa protein recognized as sugar ABC
transporter ATP-binding protein. To induce the beneficial effects
on the host, bifidobacteria must be able to survive and persist
in the gut. This is possible not only by using an adhesion or
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TABLE 2 | Identification of immunoreactive proteins isolated from Bifidobacterium strain.
Strain
number
Estimated molecular
weight of isolated
protein [kDa]
Homologous protein
name Accession No.
Nominal molecular
weight of
homologous
proteins [kDa]
Origin of
homologous
protein
Homology [%] Method of
isolation
Immunoreactivity
B
ifi
d
o
b
a
c
te
ri
u
m
lo
n
g
u
m
ss
p
.
lo
n
g
u
m
C
C
M
7
9
5
2 43 Enolase
ZP_00120494.2
46.6 Bifidobacterium
longum DJO10A
38 VI Rabbit sera against
B. longum ssp.
longum CCM 7952
20 Aspartokinase
WP_007051616.1
18.6 Bifidobacterium
longum
NCC2705
47 V Rabbit sera against
B. longum ssp.
longum CCDM 372
55 Pyruvate kinase
ADC85999.1
52.5 Bifidobacterium
animalis subsp.
lactis BB12
70 IV, V Rabbit sera against
B. longum ssp.
longum CCDM 372
67 Molecular chaperone
DnaK NP_695712.1
66.9 Bifidobacterium
longum
NCC2705
30 III, IV, V Rabbit sera against
B. longum ssp.
longum CCDM 372
60 Hypothetical protein
BIFLAC_06461
ZP_02963269.1
62 Bifidobacterium
animalis subsp.
lactis HN019
30 III, VI Rabbit sera against
L. paracasei LCOK
0912
B
ifi
d
o
b
a
c
te
ri
u
m
lo
n
g
u
m
ss
p
.
lo
n
g
u
m
C
C
D
M
3
7
2
40 Sugar ABC transporter
ATP-binding protein
NP_695858.1
40.7 Bifidobacterium
longum
NCC2705
37 VI Sera from germ
mice colonized with
Bifidobacterium
longum ssp. longum
CCDM 372
94 Not identified III, IV, V, VI Rabbit sera against
B. longum ssp.
longum CCDM 372
66 Penicillin-binding protein
3 peptidoglycan
synthetase EDT88982.1
65.3 Bifidobacterium
animalis subsp.
lactis HN019
65 III, IV, V Rabbit sera against
B. longum ssp.
longum CCM 7952
or CCDM 372
55 Pyruvate kinase
WP_014697813.1
52.6 Bifidobacterium
animalis subsp.
animalis ATCC
25527
53 III, IV, V Rabbit sera against
B. longum ssp.
longum CCDM 372
43 Phosphoglycerate kinase
NP_695890.1
46.6 Bifidobacterium
longum
NCC2705
39 III, IV, V, VI Rabbit sera against
B. longum ssp.
longum CCM 7952
or CCDM 372
35 Transaldolase
ZP_04664439.1
39.7 Bifidobacterium
longum subsp.
infantis CCUG
52486
24 III, V Rabbit sera against
B. longum ssp.
longum CCDM 372
30 1-(5-phosphoribosyl)-5-
[(5-phosphoribosylamino)
methylideneamino]
imidazole-4-carboxamide
isomerase
ZP_02963768.1
25.7 Bifidobacterium
animalis subsp.
lactis HN019
50 VI Rabbit sera against
B. longum ssp.
longum CCM 7952
or CCDM 372
22.6 50S ribosomal protein L5
ZP_02963325.1
22 Bifidobacterium
animalis subsp.
lactis HN019
40 VI Rabbit sera against
B. longum ssp.
longum CCM 7952
or CCDM 372
20 30S ribosomal protein S9
BAJ69893.1
17.5 Bifidobacterium
longum subsp.
infantis ATCC
15697
73 III Rabbit sera against
B. longum ssp.
longum CCM 7952
or CCDM 372
(Continued)
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TABLE 2 | Continued
Strain
number
Estimated molecular
weight of isolated
protein [kDa]
Homologous protein
name Accession No.
Nominal molecular
weight of
homologous
proteins [kDa]
Origin of
homologous
protein
Homology [%] Method of
isolation
Immunoreactivity
17 30S ribosomal protein
S16 Q8G7G1.1
16.4 Bifidobacterium
longum NCC
2705
79 III Rabbit sera against
B. longum ssp.
longum CCM 7952
or CCDM 372
14 50S ribosomal protein
L15 WP_008783622.1
15.8 Bifidobacterium
longum subsp.
infantis ATCC
15697
60 III Rabbit sera against
B. longum ssp.
longum CCM 7952
or CCDM 372
45 Glyceraldehyde
3-phosphate
dehydrogenase C
KFI73119.1
39.3 Bifidobacterium
minimum
40 III Human sera from
patients with acute
C. difficile infection
60 Hypothetical protein
BIFLAC_06461
ZP_02963269.1
62 Bifidobacterium
animalis subsp.
lactis HN019
30 III, V, VI Rabbit sera against
L. paracasei LOCK
0912
colonization factors, but also by production specific substances
allowed them to recruitment the energy from the fermentable
carbohydrates not absorbed or metabolized by the host. He et al.
(2007) demonstrated that bifidobacteria are able to utilize a
wide range of catabolic pathways using enzymes for metabolism
of lactose, glucose and galactose. Schell et al. (2002) provided
a genome analysis of Bifidobacterium longum and identified
several major proteins, including 26 solute binding proteins of
ABC transporter systems which could be important in terms of
colonization in the gut and nutrient availability or involved in the
immunomodulatory activity of bifidobacteria. It was also shown
that the ATP binding protein of ABC transporter for sugars
increased abundance during interaction of B. longum with Caco-
2 (Wei et al., 2014) and they are expressed under oxygen stress
(Xiao et al., 2011) or under bile exposure (Ruiz et al., 2009).
One of the key findings of this work is the identification
of several immunogenic protein of CCDM 372 reacting with
rabbit homologs sera and sera against strain CCM 7952. In
particular, peptidoglycan synthetase penicillin-binding protein 3,
pyruvate kinase, phosphoglycerate kinase (PGK), transaldolase
and different ribosomal proteins. Ruiz et al. (2009) found
five ribosomal proteins of Bifidobacterium longum biotype
longum NCIMB 8809 to be overproduced in the presence of
bile. Previously, several surface-associated ribosomal proteins
have been also identified in Streptococcus suis (Aranda et al.,
2009), Streptococcus pyogenes (Ventura et al., 2003) and
Lactobacillus rhamnosus GG (Sánchez et al., 2009) where
they are involved in sensing the environmental changes.
Transaldolase has been already shown to be release into
medium (Sánchez et al., 2008). In addition, it was also detected
in the extracellular proteome of B. animalis subsp. lactis
BB12 (Gilad et al., 2011). Recently, González-Rodríguez et al.
(2012) indicated that this protein could act as an important
colonization factor favoring Bifidobacteria establishment in
the gut.
Interestingly, we indicated that non-immune human sera,
not only of adult blood donors, but also from umbilical cord
sera, didn’t contain antibodies recognizing proteins isolated from
both bifidobacteria strains. However, we observed the cross-
reactivity of 45 kDa protein isolated from B. longum subsp.
longum CCDM 372 with sera from patients with Clostridium
difficile infection. This protein was identified as glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), which is one of the earliest
examined moonlighting protein and their multifunctional nature
as adhesins as well as plasminogen receptors had been well
characterized (Jin et al., 2005; Terrasse et al., 2012; Giménez
et al., 2014). The immune response against GAPDH have been
described for numerous pathogens i.e., S. aureus (Kerro-Dego
et al., 2006), Edwarsiella tarda (Li et al., 2012), Streptococcus
iniae (Ra et al., 2009), Streptococcus agalactiae (Liu et al., 2013).
In our previous work we indicated that GAPDH is at least
one of immunogenic protein of Lactobacillus johnsonii 142
and immunoreactive protein of probiotic L. rhamnosus LOCK
0900 and suggested the importance of this protein in cross-
talk between bacteria and their host (Górska et al., 2016).
Recently, it has been suggested that GAPDH possesses role in
host-immune responses, modification of intracellular signaling
and evasion from immune surveillance of the host (Perez-
Casal and Potter, 2016). The ability of GAPDH to bind to
extracellular matrices, modulation of host-immune responses, a
role in virulence and surface location has prompted investigators
to postulate that GAPDH may be a good vaccine candidate
for protection against numerous pathogens. However, it is
reasonable to think that immune response against the GAPDH
may also result in deleterious effect to the host due to cross-
immune reactions. Alignment of the Bifidobacterium longum
GAPDH protein sequence with some pathogens i.e., Clostridium
difficile, Shigella flexneri, Salmonella enterica, Escherichia coli and
probiotic bacteria i.e., L. rhamnosus GG, Lactobacillus reuteri
JCM 1112, Lactobacillus helveticus CNRZ32 or human GAPDH
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proteins using Clustal Omega reveals a high degree of homology.
For instance, the homology of GAPDH between B. longum and
human, C. difficile, E.coli is around 42, 50, and 60%, respectively
and between B. longum and L. rhamnosus GG shared homology
of 68%. It will be interesting to identify epitopes of these protein
that evoke protective immune response and open the possibility
to use Bifidobacterium GAPDH as an antigens for development
of vaccines.
This study demonstrates for the first time that glycolytic
enzymes, other metabolic enzymes, molecular chaperones or
ribosomal protein from human Bifidobacterium isolates are able
to induce the immune response and elicited antibodies in strain
dependent manner. This observation raise the question of the
impact of this protein in the mechanism of the Bifidobacterium–
host interaction. We indicated that the protein extraction
methods and analysis of immunoreactivity could be suitable
to differentiate among the species of bifidobacteria and their
biological function. The immunoreactive proteins identified in
our study open a new potential possibilities of using them
as medically important molecules i.e., vaccines development;
however the further analysis are needed to provide the details
about the biological nature of specific antigens and to select the
best candidates.
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